Jianfeng Group Pro 2017-024 (Announcement on Authorizing Chairman to Decide to Entrust Financial Management)
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2017-024
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
on Authorizing the Chairman to Decide to Entrust Financial Management
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Important Note:
● Entrusted Financial Management Amount: Authorizes the Chairman of the Board to exercise the decision-making power of entrusted financial management not exceeding RMB 2 .9 billion Yuan. Funds within this amount can be used in a rolling manner, but the total amount of entrusted financial management remaining at any time point shall not exceed RMB 0.2 billion Yuan .
● Type of entrusted wealth management investment: Select varieties with high security, good liquidity and low risk to carry out entrusted wealth management business.
● Duration of entrusted financial management: The duration of each entrusted financial management shall not exceed 12 months.
1. Overview
Basic Information of (I)
1 . Principle: The company will take "Standardize operation, prevent risks, invest prudently and maintain and increase value" as the principle.
2 , varieties: choose high security, good liquidity, low risk varieties to carry out entrusted financial management business.
3 , funds: phased idle own funds.
4 , Authorized Amount and Term: Authorized Chairman of the Board of Directors to exercise the decision-making power of entrusted financial management not exceeding RMB 2 .9 billion, within which funds can be used on a rolling basis, but the total balance of entrusted financial management existing at any point in time shall not exceed RMB 0.2 billion. The term of each entrusted financial management shall not exceed 12 months. The authorization period shall be valid for 3 years from the date of approval by the board of directors of the company. The specific investment activities are organized and implemented by the Company's Finance Department.
5 , Implementation: Authorize the chairman of the board to decide on matters related to entrusted financial investment within the above amount, including but not limited to: selecting qualified professional financial institutions, selecting specific types of entrusted financial products, specifying the amount and duration of entrusted financial management, signing relevant contracts and agreements, etc.
(II) the approval procedures to be performed within the company
on August 25, 2017 , the 15th meeting of the 9th board of directors held by the company deliberated and passed the proposal on authorizing the chairman of the company to use idle self-owned funds for entrusted financial management. Voting result: 9 votes in favor, 0 votes against and 0 abstentions.
2. main content(I) entrusted funds source:
phased idle self-owned funds .
The impact of (II) on the company1
, the company uses phased idle self-owned funds for entrusted financial management, which is implemented on the premise of ensuring the company's daily operation and capital safety, and does not affect the company's daily capital turnover, Does not affect the normal development of the company's business operations.
2. By conducting moderate and low-risk financial product investment business, we can improve the efficiency of capital use, obtain certain investment benefits, and seek more investment returns for the company's shareholders.
(III) Risk Control AnalysisThe company strictly follows the "Entrusted Financial Management System" approval and implementation procedures to ensure the effective development and standardized operation of entrusted financial management and other investment businesses. However, as the financial market is greatly affected by the economic environment, it is not ruled out that investment businesses such as investment and wealth management will be affected by market fluctuations. The company will take the following measures:
(1
) The company will clearly assign special personnel to be responsible for such investment matters Related work: the chairman of the company exercises such investment decision-making power and signs relevant contract documents, the company's financial officer is responsible for organizing the implementation, and the specific operations.
(2) The company's finance department is responsible for timely analysis and tracking of the investment direction of financial products and the progress of investment projects. If the evaluation finds that there are conditions that may affect the company's capital security or affect the normal capital flow demand, corresponding preservation or redemption measures will be taken in a timely manner to control investment risks.
(3) The audit department of the company is responsible for auditing and supervising various investments, regularly auditing and verifying the progress, profit and loss, risk control, etc. of entrusted financial management, and evaluating the possible risks and benefits of various entrusted financial management according to the principle of prudence, and reporting to the audit committee of the board of directors.
(4) The office of the board of directors of the company fulfills its information disclosure obligations in accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange.
Opinions of (IV) Independent DirectorsThe independent directors of the company issued independent opinions on the resolution, and believed that: the approval procedures of the proposal comply with laws and regulations and the relevant provisions of the company's Articles of Association; the company complies with national laws and regulations and Under the premise of ensuring the safety of investment funds, carrying out entrusted wealth management business with its own funds is conducive to improving the efficiency of fund use and obtaining certain benefits, it is in the interests of the Company and all shareholders, and there is no harm to the interests of the Company and all shareholders, especially the small and medium shareholders.
3. As of the date of this announcement, the company's accumulated entrusted financial management
| serial number | trustee | financial management product type | amount (ten thousand yuan) | start date | due date | Amount Recovered as of Announcement Date (RMB 10,000) |
Income as of Announcement Date (RMB 10,000) |
| 1 | Guangfa Bank Jinhua Branch | Salary Increase 16 5876 RMB Structured Deposit Product | 5,000.00 | 2017/4/6 | 2017/7/5 | 5,000.00 | 51.16 |
| 2 | Bohai Bank Jinhua Branch | Bohai Bank S17180 Structured Deposit Financial Product | 3,000.00 | 2017/5/17 | 2017/6/19 | 3,000.00 | 10.58 |
| 3 | Bohai Bank Jinhua Branch | Bohai Bank S17265 Structural deposit wealth management product | 3,000.00 | 2017/6/23 | 2017/7/27 | 3,000.00 | 12.30 |
| 4 | Guangfa Bank Jinhua Branch | salary and salary increase No. 16 J0253 RMB structured deposit product | 4,000.00 | 2017/7/6 | 2017/10/9 | ||
| 5 | CGB Jinhua Branch | Salary Increase No. 16 J352 RMB Structured Deposit Product | 4,000.00 | 2017/7/28 | 2017/11/13 |
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
August 29, 2017
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page